Treatment and Co-Management of mCRPC Patients with Aggressive Disease

Author(s):

Jose De La Cerda III, MD, MPH

This video segment explores treatment approaches for PSMA-positive mCRPC patients, algorithms for monitoring liver dysfunction in advanced CRPC, and exciting advancements in mCRPC treatment.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Bone Predominant mCRPC Patient Case

EP: 2.Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EP: 3.Abiraterone Acetate Versions for Treatment of mCRPC

EP: 4.Patient Selection Criteria for Different Versions of Abiraterone Acetate in mCRPC

EP: 5.Assessing Treatment Efficacy: Communication with Patients and Caregivers

EP: 6.Patient with mCRPC and Hepatic Disease

Now Viewing

EP: 7.Treatment and Co-Management of mCRPC Patients with Aggressive Disease

Video content above is prompted by the following:

If the patient is positive for prostate-specific membrane antigen (PSMA), how would you treat the patient?
What is your algorithm for monitoring patients with liver dysfunction and advanced CRPC?
What advances in treatment of mCRPC are you most excited about?

Related Videos

Resective Surgery and Minimally Invasive Procedures For BPH

Operationalizing TAR-200 and Other Delivery Systems in Practice

Unmet Needs in NMIBC

Checkpoint Inhibitors for Treatment of NMIBC

Communication of Treatment Options for High-Risk NMIBC

Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment

BPH: The Patient Journey

Addressing Remaining Unmet Needs in mCRPC

Use and Sequencing of Novel Treatments in NMIBC